AIM ImmunoTech market cap is $9.6 m, and annual revenue was $367 k in FY 2018

AIM ImmunoTech Gross profit (Q3, 2019)-169 K

AIM ImmunoTech Gross profit margin (Q3, 2019), %(277%)

AIM ImmunoTech Net income (Q3, 2019)-2.9 M

AIM ImmunoTech EBIT (Q3, 2019)-3.2 M

AIM ImmunoTech Cash, 30-Sept-20199.6 M

AIM ImmunoTech EV4.6 M

AIM ImmunoTech revenue was $367 k in FY, 2018

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|

## Revenue | 161.0k | 213.0k | 150.0k | 197.0k | 133.0k | 92.0k | 437.0k | 367.0k |

| 31% | (32%) | (31%) | |||||

## Cost of goods sold | 1.0m | 2.0m | 1.2m | 1.3m | 1.6m | 1.1m | 1.2m | 884.0k |

## Gross profit | (882.0k) | (1.8m) | (1.1m) | (1.1m) | (1.5m) | (1.0m) | (746.0k) | (517.0k) |

| (548%) | (834%) | (723%) | (535%) | (1102%) | (1104%) | (171%) | (141%) |

## R&D expense | 6.7m | 9.5m | 8.4m | 9.0m | 8.0m | 5.1m | 4.1m | 4.8m |

## General and administrative expense | 6.7m | 9.1m | 7.7m | 9.1m | 7.1m | 7.7m | 6.6m | 6.2m |

## Operating expense total | 13.4m | 18.6m | 16.1m | 18.0m | 15.2m | 12.8m | 10.7m | 11.0m |

## EBIT | (14.3m) | (20.3m) | (17.2m) | (19.1m) | (16.6m) | (13.8m) | (11.4m) | (11.5m) |

| (8879%) | (9549%) | (11445%) | (9695%) | (12519%) | (15004%) | (2612%) | (3132%) |

## Interest expense | 41.0k | 24.0k | 16.0k | 11.0k | ||||

## Interest income | 364.0k | 129.0k | 88.0k | |||||

## Net Income | (9.0m) | (17.4m) | (16.2m) | (17.4m) | (15.2m) | (7.5m) | (8.3m) | (9.8m) |

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|

## Net Income | (9.0m) | (17.4m) | (16.2m) | (17.4m) | (15.2m) | (7.5m) | (8.3m) | (9.8m) |

## Depreciation and Amortization | 465.0k | 643.0k | 867.0k | 1.1m | 1.2m | 1.1m | 948.0k | 856.0k |

## Accounts Receivable | (24.0k) | (1.1m) | ||||||

## Inventories | (110.0k) | (579.0k) | (1.3m) | |||||

## Accounts Payable | 424.0k | 860.0k | (617.0k) | 869.0k | (196.0k) | (326.0k) | 566.0k | 166.0k |

## Cash From Operating Activities | (10.1m) | (13.1m) | (16.8m) | (13.9m) | (16.1m) | (7.4m) | (7.9m) | (10.6m) |

## Purchases of PP&E | (1.8m) | (5.8m) | (898.0k) | (504.0k) | (240.0k) | (160.0k) | (20.0k) | (51.0k) |

## Cash From Investing Activities | 8.7m | (16.1m) | 22.3m | 2.5m | 6.4m | 2.9m | 2.7m | 92.0k |

## Long-term Borrowings | (71.0k) | (47.0k) | (45.0k) | (34.0k) | (264.0k) | |||

## Dividends Paid | 388.0k | |||||||

## Cash From Financing Activities | 1.6m | 28.3m | (6.8m) | 12.8m | 9.7m | 4.8m | 4.2m | 9.4m |

## Net Change in Cash | 183.0k | (891.0k) | (1.4m) | 1.4m | (41.0k) | 293.0k | (996.0k) | (1.1m) |

## Interest Paid | 3.0k | 101.0k | 328.0k |

USD | Y, 2019 |
---|---|

## EV/EBIT | -1.4 x |

## EV/CFO | -0.7 x |

## Financial Leverage | 1.6 x |